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Abstract
Aim In this original article, we seek to analyse the
environment in which immunisation policies are adopted
and, more specifically, the way the public perception of
vaccines influences decision-making, by looking more
closely at the case of Switzerland.
Subjects and methods Historical and present-day examples
of attitudes towards immunisation and specific vaccines,
both on the part of the public and of health-care workers,
are reviewed.
Results Decision-making with regard to vaccine policy
implementation has been and is still most often driven by
fear: fear of disease (when perceived as rampant and/or
dangerous), but also fear of vaccine-associated adverse events
(when the disease is less or no longer “visible”). However,
methodology for introducing evidence-based immunisation
policies exists and can be used by public health authorities,
while vaccination information systems (such as the Swiss
InfoVac) have proven their usefulness in providing trustwor-
thy, peer-based knowledge to health-care workers.
Conclusion Only information based on clear, evidence-
based data gathered and analysed according to solid
methodological criteria coupled with adequate information
of health-care workers (and thus patients) can ensure in
future the implementation of scientifically coherent, pub-
licly acceptable, and equitable immunisation policies.
Keywords Evidence-based medicine .
Immunisation policy . Vaccine-associated adverse events .
Vaccines
Background: public perception of vaccines based
on fear
Whether we like it or not, the public acceptability of
vaccines is largely dependent on fear. When a disease is
perceived as dangerous, people are eager to be protected,
even if a varying degree of opposition to immunisation as
such has always existed. Many historical examples illus-
trate this fact. For instance, the ravages wrought by
poliomyelitis was the main incentive for over 400,000
American children to take part in what was then (1955) the
largest clinical trial of a vaccine (Salk’s inactivated polio
vaccine, IPV) (Blume and Geesink 2000). Shortly before
(1948–1951) nearly 14 million people were inoculated with
BCG within the International Tuberculosis Campaign,
despite debate surrounding the efficacy and safety of the
vaccine. However, the willingness to use BCG cannot be
separated from the dread of tuberculosis, particularly in the
aftermath of the Second World War (Comstock 1994;
Bryder 1999).
Fear, however, like all emotions, is a subjective and
fickle feeling that may not (and indeed often does not)
focus on the right target. Whereas the number of people
killed in airplane crashes pales in comparison with those
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who lose their lives due to automobile accidents, more
people are afraid of flying than of driving. Nor is science
the answer to all: how many of us would jump out of an
airplane without a parachute, despite the fact that no
randomised controlled trial has “scientifically” proven the
protection conferred by parachutes when falling through
space (Gordon et al 2003)! The same is true in public health
and in particular in the area of immunisation.
Following the “epidemiological transition” in most
industrialised countries (i.e. chronic diseases come far
before infectious diseases in terms of causes of death), the
fear of vaccine adverse events now outweighs the fear of
the diseases themselves, in large part because these diseases
are no longer visible (paradoxically) thanks to vaccination.
And yet if one considers the World Heath Organisation
(WHO) European objectives regarding vaccine-preventable
diseases, even a country like Switzerland has reached only
three goals out of eight (see Table 1).
Research has shown for instance that 4 months after 11
September 2001 over 65% of Canadian adults would have
readily agreed to be immunised against anthrax and more than
50% against smallpox, regardless of the fact that their
exposure to such diseases was nil. In contrast, only a little
over 37% would have agreed to be vaccinated against HIV
(Ritvo et al 2003), probably because they considered
themselves as not exposed and/or because of treatments
being available (regardless of their severe side effects, often
underestimated or unknown to the larger public), HIVAids is
increasingly regarded as a chronic, non-fatal disease. Another
variation on this theme can be seen in France where parents
whose children were vaccinated against hepatitis B virus
(HBV) during the 1994–1998 campaign as well as parents
whose children were over 18 years of age in 2003 had a
more favourable attitude towards the HBV vaccine than other
parents. This can be attributed at least in part to the fact that
they were not confronted with the dilemma of vaccinating or
not their offspring following a nationwide scare that HBV
vaccine caused multiple sclerosis and a variety of autoim-
mune diseases (Balinska and Léon 2007).
This again shows just how fickle fear is. In addition, our
memory is short: need we remind ourselves that fear of
bioterrorism (anthrax, smallpox...) following “9/11” was
soon replaced by fear of SARS in 2003 and of pandemic
influenza in 2005. Predicting which fear will come next is
indeed challenging.
In Switzerland, over 90% of parents fear meningitis,
tetanus, and polio because of the possibility of brain
damage, but only 30 to 40% are afraid of pertussis,
measles, mumps, or rubella for their children. As a result,
over 96% of children are immunised against the first three
diseases, whereas 15% of 2 year olds are not vaccinated
against the four latter. In actual fact, the risk of brain
damage in Switzerland is higher for measles than for
meningitis, tetanus, or polio.
Fear can be useful, of course, because it helps in
introducing a new vaccine - at least to begin with. For
example, the implementation of Haemophilus influenzae
type B (Hib) vaccine was very effective in Switzerland
precisely because of the scariness of the disease. As a
result, Hib incidence was brought down by 80% in less than
3 years (Mühlemann et al. 1996). But the same fear is
associated with meningococcal C disease, whereas its
extremely low incidence (only 0.5/ 100,000) hardly justifies
the introduction of a full-fledged vaccination programme.
Yet how can we not develop recommendations for this
much demanded vaccine and how can a physician refuse its
administration to the child of anxious parents, especially if
the main reason is that the vaccine is “too expensive”? This
type of situation raises above all ethical issues. In Switzer-
land, for example, paediatricians confirmed having adminis-
trated meningococcal C vaccine to their own children while
not being in a position to offer it to their patients (Postfay-
Barbe et al. 2005).
As a result of the success of the Hib immunisation
programme, parents and physicians have not been con-
fronted with the disease in the past decade, and some of
them “logically” conclude that vaccination is no longer
necessary, or at least as necessary as it was. The question
may be raised as to what will occur 20 to 30 years hence if
we are effective in introducing human papillomavirus
vaccine (HPV) immunisation programmes. It is perfectly
reasonable to predict that it will be increasingly difficult to
convince parents to have their adolescent girl immunised
against cervical cancer, a disease which will have vanished,
if not disappeared.
In contrast, rotavirus gastroenteritis is an extremely
common form of diarrhoea in young children and therefore
not perceived as dangerous. Although rotavirus constitutes
an important disease burden throughout the world (with
high mortality in developing countries), the actual number
of ensuing deaths is negligible in privileged countries
where access to medical care is as rapid as in Switzerland.




Tetanus Elimination neonatal Yes
Poliomyelitis Elimination Yes
Pertussis Incidence <1/100,000 No
Measles No deaths No
Incidence <1/100,000 No
Rubella Elimination pregnant women No
Elimination congenital No
Mumps Incidence <1/100,000 No
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Nevertheless, the REVEAL study has estimated that
23.6 million children in the European Union are effected
by rotavirus gastroenteritis (RVGE) every year, resulting in
some 231 deaths, over 87,000 hospitalisations, and about
700,000 outpatient visits. Seasonal peaks of RVGE are an
important cause of hospitalisation for small children,
incurring heavy direct medical costs; thus, the introduction
of an effective immunisation programme could greatly
decrease both distress and costs (Gabutti et al. 2007).
It goes without saying that decisions based on fear are
not always wise. In spring 2003, an outbreak of measles in
Switzerland resulted in 671 cases, leading to 15% of
complications, including 4 cases of encephalitis. In 2007,
more than 1,000 measles cases were again reported in an
outbreak that lasted for more than a year (Richard and
Spicher 2007) and is still ongoing with more than 2,300
reported cases by March 2008. Switzerland is hardly an
exception: measles outbreaks have been reported in the
Netherlands (1999–2000, 3,292 reported cases in which
94% of the patients had not been vaccinated) (Van den Hof
et al 2002), in Campania, southern Italy, (2002–2003, some
20,000 cases with more than 5,000 associated hospital-
isations) (Filia 2007), France (2003, 89 cases in Marseilles
with a shift to older persons) (Zandotti et al. 2004), and
Germany (2003: 246 reported cases in the western part of
the country with 52 hospitalisations) (Eurosurveillance
Editorial Team 2006). Reasons for insufficient coverage
may range from fear of adverse events (such as in the UK)
to problems of accessibility (such as in southern Italy) or to
a preference for “natural” medicine (the Netherlands,
northeastern Switzerland, and southeastern France). And
once again, we face not only an epidemiological problem,
but an ethical dilemma, for as one author rightly put it:
“unvaccinated clusters pose a risk to themselves and to
surrounding vaccine-accepting individuals” (Van den Hof et
al 2002). In addition, as time has shown, the use of
effective vaccines reduces disease burden and thus the fear
of those diseases.
In privileged countries where public health systems are
able to offer a large range of preventive vaccines to almost all
children, fears may select the wrong targets. Besides specific
vaccine “panics”, such as HBV vaccine and multiple sclerosis
in France, or Measles-Mumps-Rubella (MMR) vaccine and
autism in the UK (spreading to other English-speaking
countries), there is more and more talk about the possible
relation between vaccines and various worrying conditions or
concepts, most of which have been refuted or shown to be
highly improbable on the basis of available scientific
evidence. These fears include vaccines and “immune over-
load” (Gregson and Edeman 2003; Offit et al. 2002), vaccines
and allergies (Sanchez-Solis and Garcia-Marcos 2006;
Koppen et al. 2004), vaccines and autoimmune diseases
(Mikaeloff et al. 2007a, b), not to mention suspicions raised
over adjuvants (such as mercury and aluminium) (Goriely
and Goldman 2007; Siegrist 2007; Davies et al. 2002; Wolfe
et al. 2002; Zimmerman et al. 2005) or AIDS (Elswood and
Stricker 1994) and cancer. The more recent “epidemic” of
obesity in children has also been related to vaccines. And yet
the fact remains that the risk of severe adverse events with
current vaccines is estimated at 1 to 10 per million. These
include anaphylaxis (0.5/million), vaccine-attributed paralyt-
ic poliomyelitis (VAPP) due to oral poliomyelitis vaccine
(OPV) (1.3/million), and acute demyelinating encephalopa-
thy (1/million?) (Chen 1996). It has thus become clear that
the public perception of vaccines challenges the health of the
population at large.
We will still be working for at least another century on
the problem of coincidental (or temporal) association
between vaccine administration and disease states. Influen-
za vaccination was briefly suspended in Israel following
four deaths temporally associated with the vaccine, until all
causal relationship was ruled out [Influenza team (ECDC)
2006]. These kinds of problems will necessarily increase as
the number of new vaccines rises.
One way of dealing with them is to develop statistics on
background occurring diseases (number of cases, deaths,
etc., expected in the target population regardless of
intervention), as for example has been done in view of
HPV vaccine introduction in Switzerland (Siegrist et al.
2007). By computing the use of medical resources one can
monitor an entire range of illnesses affecting the target
population, which remains beyond the reach of cohort
studies. A more difficult challenge is how we, health
professionals, should explain relatively complex notions
such as time and space clustering, temporal associations -
not to mention the difference between adverse events
following vaccination (which may or may not be linked to
the vaccine), and vaccine adverse effects (recognised
undesirable effects usually affecting a very small minority
of individuals). These questions are all the more crucial
since a number of chronic diseases are on the rise for
reasons unknown to us (diabetes mellitus, autoimmune
diseases, etc.). Fears are often specific to countries and/or
cultures, but are also perfectly capable of crossing frontiers,
particularly with the growing phenomenon of information
seeking on the Web.
Finally, over the past 50 years faith in religious and
health authorities and trust in politicians has decreased
importantly. This can be attributed to a number of reasons,
including HIV-contaminated blood scandals, “mad cow”
disease, “patient” status veering more and more towards
“client” status, as well as the confusion between access to
information, increasingly easily available on the Web, and
appropriate validation and use of such information.
The one way forward thus remains evidence-based
decision making.
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The need for evidence-based public health decisions
New vaccines must be evaluated in a comprehensive and
systematic way, based on available evidence. This is not as
easy as it might seem. Decision-making regarding new
vaccines needs to follow criteria that are not influenced by
labile public fears, lobbying influences of profit-seeking
industries, audience-seeking media, personal expectations
from members of Advisory Committees, and competing
political or financial priorities. The evaluation of new
vaccines must be comprehensive, systematic, evidence-
based, standardised, and reproducible. It must be capable of
assuring the homogeneity and equity of immunisation
programmes, taking into consideration societal factors such
as acceptance and equity in access to health prevention
measures. This is not an easy task.
Analytical frameworks for evidence-based vaccine rec-
ommendations have been developed and should be used.
Health Canada provided a useful list of such recommenda-
tions, which was adopted and adapted by Switzerland in
2004 (see Table 2). Similar parameters are included in other
frameworks, whether public or not. Different sorts of
scenarios could be cited when describing the prevention
of disease through the use of vaccinations. For the purpose
of the examples being illustrated in the present article, we
present three such scenarios.
In the first scenario, the public health benefit of
vaccination is greater than or equal to the individual
benefit. Four kinds of diseases enter into this scenario:
severe diseases with high incidence (for example, polio in
the 1960s or HPV-associated neoplasia nowadays), severe
diseases with low incidence but no other effective means of
prevention or treatment (for example, hepatitis B in certain
countries), transmissible diseases currently controlled but
requiring that a high vaccine coverage be maintained (for
example, diphtheria), and transmissible diseases requiring a
high vaccine coverage in order for society to benefit from
herd immunity effects (for example, measles and pertussis).
In the second scenario, the benefit of vaccination is
limited to certain well-defined high-risk groups. This means
groups of individuals at greater risk of complications owing
to their age or underlying conditions (immunodeficiency,
certain chronic diseases, etc.) and consequently more likely
to develop complications due, for example, to influenza.
But there are also groups who are more exposed to diseases
than others: for example, health-care workers (here again
one can cite the examples of hepatitis B and influenza
viruses), occupational risks (teachers, social workers, and
tuberculosis), or people travelling from a specific disease-
free country to a country where that disease is prevalent (for
example, yellow fever).
Finally, in the third scenario, the individual benefit is
greater or equal to the public health benefit. Such a scenario
concerns severe diseases with low incidence (for example,
meningococcal C disease), less severe diseases in that they
very rarely cause permanent sequelae but occur at a high
incidence in individuals without defined or controllable risk
factors (for example, rotavirus gastroenteritis), and less
severe diseases lacking alternative methods of prevention
and/or treatment (for example, varicella in young children).
This third scenario raises important ethical issues: if no
official recommendations exist for these vaccines, parents
will have at best partial information and, more likely, none.
It follows that all effective and safe vaccines should benefit
from specific evidence-based recommendations in order to
ensure the right to information even in the absence of
public health benefit - and even if the recommendation is
that a vaccine is not “worth” administering to every one.
Efforts should equally be made to ensure equitable access
to prevention (principally through reimbursement schemes).
However, simply to add such vaccines to routinely
recommended vaccines that confer both public health and
individual benefit carries the risk of seeing parents select
vaccines based on the perceived risks of disease. In such a
scenario, measles and pertussis vaccines would continue to
rank after group C meningococcus vaccines, despite the
evidence.
In the face of an increasingly complex context of vaccine
preventable diseases, Switzerland felt the need to introduce
a new category of recommendations.
1. Recommended baseline vaccines. Such vaccines are
required for both individual and public health, confer-
ring a level of protection required for the well-being of
the population through herd immunity. These vaccines
must be recommended by physicians to their patients.
2. Recommended complementary vaccines. Such vaccines
confer optimal individual protection against well-
defined risks without a major public health impact.
Physicians must inform their patients of the existence
of these vaccines (right to information and choice).






Acceptability of immunisation programme
Feasibility of immunisation programme
Capacity to evaluate the programme
Open research questions
Equity of the programme
Legal considerations
Conformity of the recommendations
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3. High risk group vaccines. Such vaccines provide
sufficient benefit to certain well-defined patients to
justify that physicians make appropriate efforts to
identify high-risk individuals belonging to these groups
and recommend them.
In order to facilitate this process at all levels, every one
has a role to play. Health authorities are there to identify
baseline vaccines as targets requiring specific programme
objectives (minimal target coverage, surveillance) and
facilitate the allocation of resources going beyond vaccines
and vaccinators to include promotion. Health-care workers
are in a key position to facilitate communication by
indicating clearly where the emphasis should be put, i.e.
measles-mumps-rubella (MMR) vaccine should come far
before meningococcal C vaccine. As for hesitating parents,
they naturally focus on issues of individual relevance when
making their decisions. For them, their child’s health will
clearly be placed higher than public health interests. They
also have choices to make around optimal protection and
minimal injections.
Discussion: evidence-based implementation of vaccine
recommendations
Evidence-based recommendations must evolve annually
to adapt to an ever changing world. Evidence-based
implementation of vaccine recommendations means es-
sentially ensuring that recommendations are supported by
the health-care workers (HCW) in charge of their
administration. The question is how to gain, improve,
and maintain HCW endorsement. In Switzerland, a
survey showed in 2004 that 43% of paediatricians based
their decision to vaccinate on their own judgement rather
than on official recommendations. This illustrates a
potentially dangerous situation and the need to support
the endorsement of evidence-based recommendations by
the HCW in charge.
At the initiative of the Vaccinology Chair of the
University of Geneva, Switzerland has developed an expert
information network called InfoVac, which was initiated in
2001 and subsequently “imported” and adapted by France
(2003), Morocco (2006), and Hungary (2006). The princi-
ple and advantage of InfoVac is that it provides direct
information to HCW by an independent network of
immunisation specialists. It is supported and financed by
the Federal Office of Public Health, the Swiss Paediatric
Society, the Swiss Society of Infectious Diseases, and the
Swiss Society of Allergology and Immunology. InfoVac
runs an up-to-date website (www.infovac.ch), which has
become a recognised direct source of validated information
on vaccine-related issues. Physicians faced with a problem
or question regarding immunisation or a specific vaccine
can contact InfoVac and are guaranteed an answer from a
recognized specialist in vaccinology within 24 to 48 h.
InfoVac is appreciated notably thanks to its newsletters to
which health-care professionals can subscribe. Information
includes newly licensed vaccines, new recommendations,
updated epidemiological information (from the Federal
Office of Public Health), and product information regarding
availability, stock, and batch recalls. The network receives
over 2,500 questions per year, around 10% of which
concern vaccine safety or adverse events (Cohen and
Siegrist 2006). InfoVac also conducts literature reviews on
vaccine-related issues and publishes the responses to the
most interesting questions it has received during the
previous month. A small survey indicating that Swiss
paediatricians “follow their own judgement” also revealed
that 77% of them relied on InfoVac for the information they
need concerning immunisation (Fig. 1). This is a much
better score than that reached by official bodies, reflecting
greater peer-based than authority-based confidence and
suggesting that InfoVac is a model that might be usefully
exported to other countries.
Despite the inevitable ups and downs of science and
preventive medicine, vaccines have clearly shown their
value since the time of Jenner. Future vaccines will not
only concern the prevention of infections, but also of
chronic diseases, cancer, and addiction. With such a scope
for the improvement of public health, we must be able to
meet the challenges in terms of research, production, and
equitable access. In order to do so, we need to move on
now from a fear-based public perception of immunisation



























Fig. 1 Where do you get the information you need regarding
immunisations? Source: Switzerland, independent telephone survey,
November 2005 (n=71 paediatricians), multiple answer questions
(Courtesy Wyeth 2006)
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